



JFW
MAIL STOP AMENDMENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Y. Wu et al.

Attorney Docket No.: CCPT124975

Application No.: 10/528,350

Confirmation No.: 5046

Filed: March 17, 2005

Title: IMMUNOGEN FOR PREPARATION OF THERAPEUTIC VACCINES OR
DRUGS FOR TREATMENT OF HEPATITIS B AND THE PRODUCING
METHOD AND USE THEREOF

INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

February 7, 2006

TO THE COMMISSIONER FOR PATENTS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. X Copies of the listed non-patent literature are enclosed for the Examiner's use.
2. X Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits.
3. X The Commissioner is hereby authorized to charge any fees which may be required or credit any overpayment to Deposit Account No. 03-1740.

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}

Jeffrey M. Sakoi
Registration No. 32,059
Direct Dial No. 206.695.1713

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

Date: February 8, 2006

Shannon Lih



INFORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL TO THE
PROSECUTION OF THE SUBJECT APPLICATION

Applicants: Y. Wu et al. Attorney Docket No.: CCPT124975
Application No.: 10/528,350 Confirmation No.: 5046
Filed: March 17, 2005
Title: IMMUNOGEN FOR PREPARATION OF THERAPEUTIC VACCINES OR
DRUGS FOR TREATMENT OF HEPATITIS B AND THE PRODUCING
METHOD AND USE THEREOF

U.S. PATENT DOCUMENTS

None

FOREIGN PATENT DOCUMENTS

None

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	Cite No.	
_____	O1	An, L.-L., and J.L. Whitton, "A Multivalent Minigene Vaccine, Containing B-Cell, Cytotoxic T-Lymphocyte, and T _h Epitopes From Several Microbes, Induces Appropriate Responses In Vivo and Confers Protection Against More Than One Pathogen," <i>Journal of Virology</i> 71(3):2292-2302, March 1997.
_____	O2	Shi, T.-D., et al., "Therapeutic Peptides Based on HBcAg ₁₈₋₂₇ Epitope Can Induce CTL Response <i>In Vitro</i> and <i>In Vivo</i> ," <i>Immunological Journal</i> 19(3):165-169, May 2003.
_____	O3	Wu, Y.Z., et al, "Studies on Molecular Design, Chemical Synthesis and Immunogenicity of Novel Antigenic Peptides Against Hepatitis B Virus," <i>ACTA Academiae Medicinae Militaris Tertiae</i> 22(10):919-923, October 2000.

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicants.